Brown University Psychopharmacology Update articles from May 2007

Brown University Psychopharmacology Update archives from May 2007

Antipsychotics improve psychosocial functioning but adjunctive therapies still needed.(Latest CATIE Results)(Report)
May 1, 2007... precis * New CATIE results demonstrate that newer antipsychotic agents (olanzapine, quetiapine, risperidone, ziprasidone) and an older antipsychotic (perphenazine) all resulted in modest improvements in psychosocial functioning, with no...

CBT reduces severity of side effects in patients with panic disorder taking imipramine.(Panic Disorder)(cognitive behavioral therapy)(Report)
May 1, 2007... precis * Data were analyzed for 172 patients with panic disorder who were randomly assigned to receive imipramine alone, imipramine and cognitive behavioral therapy (CBT), or placebo * Patients receiving imipramine and CBT had less...

Drug metabolism genotypes and sertraline adverse effects.(Adverse Events)
May 1, 2007... The selective serotonin reuptake inhibitors, including sertraline (Zoloft), has been used in the management of depressed patients as well as patients with obsessive compulsive disorder (OCD). (1) There are multiple cytochrome P-450 isoenzymes...

CBT vs. paroxetine equally effective for hypochondriasis.(What's New in Research)(Medical condition overview)
May 1, 2007... precis * 16-week placebo-controlled trial compares CBT with paroxetine for severe hypochondriasis * Results suggest CBT and paroxetine are equally effective and superior to placebo, with more responders in the CBT group * All...

Tiagabine not effective for PTSD.(What's New in Research)(Post-traumatic stress disorder)(Medical condition overview)(Clinical report)
May 1, 2007... precis * Randomized, multi-center trial finds selective GABAergic drug tiagabine is not significantly more efficacious than placebo for symptoms of PTSD * Patient group is 66% women; physical/ sexual assault is most prevalent index...

SAMHSA launches database of evidence-based practices.(News Notes)(Brief article)
May 1, 2007... The Substance Abuse and Mental Health Services Administration (SAMHSA) has launched a new National Registry of Evidence-based Programs and Practices (NREPP), expanding the efforts to support local organizations in making informed decisions...

Alternative treatment for depression surveyed in women.(News Notes)(Survey)(Brief article)
May 1, 2007... A survey in a multiethnic sample of 220 women with depression found that roughly half reported past-year use of complementary or alternative medicine to treat their depressive symptoms, including chiropractic, massage, herbs and vitamins. It...

Global ADHD drug use analyzed.(News Notes)(Brief article)
May 1, 2007... In their report "The Global Market for ADHD Medications," lead researcher Richard Scheffler and colleagues write that worldwide use of drugs to treat attention-deficit/hyperactivity disorder (ADHD) more than tripled between 1993 and 2003....

Olanzapine-induced hyperglycemia in anorexia nervosa.(Case Report)(Case study)
May 1, 2007... Patient: Female, 27 years old Medications: olanzapine (Zyprexa) Case: A 27-year-old Japanese woman with a 2-year history of anorexia nervosa (restricting type) was admitted with agitation, general fatigue and fear of obesity (BMI:...

Approved: duloxetine for generalized anxiety disorder.(From the FDA)
May 1, 2007... On February 23, the FDA announced the approval of a new indication for Eli Lilly's antidepressant Cymbalta (duloxetine HCl): generalized anxiety disorder (GAD) in adults. The serotonin and norepinephrine reuptake inhibitor (SNRI) is already...

Approved: lisdexamfetamine for ADHD.(From the FDA)(Brief article)
May 1, 2007... On February 23 the FDA announced the approval of a new amphetamine-based drug--lisdexamfetamine dimesylate--to treat attention deficit hyperactivity disorder (ADHD) in children 6 to 12 years old. Maker Shire PLC claims that its drug Vyvanse...